GORDON LAYTON: Open Payments
NPI 1356075261 · HAMPSTEAD, NC. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,918 in 77 payments from 15 companies in 2025. Trend: 2023 $0 · 2024 $1,289 · 2025 $1,918
Food & beverage: $1,918
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 14 | $237 |
| AstraZeneca Pharmaceuticals LP | 5 | $220 |
| Janssen Pharmaceuticals, Inc | 5 | $217 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 5 | $196 |
| Lilly USA, LLC | 11 | $180 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 4 | $174 |
| Novo Nordisk Inc | 14 | $171 |
| PFIZER INC. | 5 | $165 |
| Supernus Pharmaceuticals, Inc. | 2 | $136 |
| Almatica Pharma LLC | 6 | $112 |
Products named: SPRAVATO, AIRSUPRA, CAPLYTA, VRAYLAR, XIFAXAN, Qelbree, MOUNJARO, NURTEC ODT.
Industry payments across NC — which companies pay providers there.
